Multiprotein-engineered cells secreting a multispecific antibody
US-2024344030-A1 · Oct 17, 2024 · US
Method for attenuating immune response using mesenchymal stem cells and cytokines
US9301979B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9301979-B2 |
| Application number | US-201414174557-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 6, 2014 |
| Priority date | Jan 31, 2008 |
| Publication date | Apr 5, 2016 |
| Grant date | Apr 5, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).
First claim
Opening claim text (preview).
What is claimed is: 1. A method for attenuating an immune response by suppressing the response of activated T-cells comprising administering an effective amount of (a) isolated mesenchymal stem cells, (b) isolated interferon gamma, and (c) isolated interleukin-1 alpha, interleukin-1 beta or tumor necrosis factor alpha, to a subject in need of treatment thereby attenuating the subject's immune response. 2. A method for inducing immunosuppression of an immu…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
- A61K35/28Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9301979B2 cover?
- The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).
- Who is the assignee on this patent?
- Univ Rutgers
- What technology area does this patent fall under?
- Primary CPC classification A61K35/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).